Tildrakizumab-Asmn (Ilumya)

Ilumya (tildrakizumab-asmn) is covered for adults ≥18 with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and is excluded for use in combination with other biologics or for off‑label indications. Key requirements: no clinically active infection, latent TB screening (and treatment if positive), evidence of prior biologic failure/intolerance OR BSA >5% OR psoriasis in vulnerable areas affecting quality of life, trial/failure of phototherapy or traditional systemic agents unless contraindicated/intolerant/unavailable, dosing per label (100 mg SC at weeks 0, 4, then every 12 weeks) and approvals for 12 months.

"Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy."

Sign up to see full coverage criteria, indications, and limitations.